1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Peripherally Acting Anti-Obesity Drug by Country/Region, 2018, 2022 & 2029
2.2 Peripherally Acting Anti-Obesity Drug Segment by Type
2.2.1 Prescription Drugs
2.2.2 Non-prescription Drugs
2.3 Peripherally Acting Anti-Obesity Drug Sales by Type
2.3.1 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Peripherally Acting Anti-Obesity Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Type (2018-2023)
2.4 Peripherally Acting Anti-Obesity Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Peripherally Acting Anti-Obesity Drug Sales by Application
2.5.1 Global Peripherally Acting Anti-Obesity Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Peripherally Acting Anti-Obesity Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Application (2018-2023)
3 Global Peripherally Acting Anti-Obesity Drug by Company
3.1 Global Peripherally Acting Anti-Obesity Drug Breakdown Data by Company
3.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Company (2018-2023)
3.1.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Company (2018-2023)
3.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Company (2018-2023)
3.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Company (2018-2023)
3.3 Global Peripherally Acting Anti-Obesity Drug Sale Price by Company
3.4 Key Manufacturers Peripherally Acting Anti-Obesity Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peripherally Acting Anti-Obesity Drug Product Location Distribution
3.4.2 Players Peripherally Acting Anti-Obesity Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Peripherally Acting Anti-Obesity Drug by Geographic Region
4.1 World Historic Peripherally Acting Anti-Obesity Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Peripherally Acting Anti-Obesity Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Peripherally Acting Anti-Obesity Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Peripherally Acting Anti-Obesity Drug Sales Growth
4.4 APAC Peripherally Acting Anti-Obesity Drug Sales Growth
4.5 Europe Peripherally Acting Anti-Obesity Drug Sales Growth
4.6 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Growth
5 Americas
5.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country
5.1.1 Americas Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023)
5.1.2 Americas Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023)
5.2 Americas Peripherally Acting Anti-Obesity Drug Sales by Type
5.3 Americas Peripherally Acting Anti-Obesity Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region
6.1.1 APAC Peripherally Acting Anti-Obesity Drug Sales by Region (2018-2023)
6.1.2 APAC Peripherally Acting Anti-Obesity Drug Revenue by Region (2018-2023)
6.2 APAC Peripherally Acting Anti-Obesity Drug Sales by Type
6.3 APAC Peripherally Acting Anti-Obesity Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peripherally Acting Anti-Obesity Drug by Country
7.1.1 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023)
7.1.2 Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023)
7.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Type
7.3 Europe Peripherally Acting Anti-Obesity Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug by Country
8.1.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Type
8.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peripherally Acting Anti-Obesity Drug
10.3 Manufacturing Process Analysis of Peripherally Acting Anti-Obesity Drug
10.4 Industry Chain Structure of Peripherally Acting Anti-Obesity Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peripherally Acting Anti-Obesity Drug Distributors
11.3 Peripherally Acting Anti-Obesity Drug Customer
12 World Forecast Review for Peripherally Acting Anti-Obesity Drug by Geographic Region
12.1 Global Peripherally Acting Anti-Obesity Drug Market Size Forecast by Region
12.1.1 Global Peripherally Acting Anti-Obesity Drug Forecast by Region (2024-2029)
12.1.2 Global Peripherally Acting Anti-Obesity Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Peripherally Acting Anti-Obesity Drug Forecast by Type
12.7 Global Peripherally Acting Anti-Obesity Drug Forecast by Application
13 Key Players Analysis
13.1 Novo Nordisk A/S
13.1.1 Novo Nordisk A/S Company Information
13.1.2 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novo Nordisk A/S Main Business Overview
13.1.5 Novo Nordisk A/S Latest Developments
13.2 Pfizer Inc.
13.2.1 Pfizer Inc. Company Information
13.2.2 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer Inc. Main Business Overview
13.2.5 Pfizer Inc. Latest Developments
13.3 Boehringer Ingelheim International GmbH
13.3.1 Boehringer Ingelheim International GmbH Company Information
13.3.2 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Boehringer Ingelheim International GmbH Main Business Overview
13.3.5 Boehringer Ingelheim International GmbH Latest Developments
13.4 KVK Tech Inc.
13.4.1 KVK Tech Inc. Company Information
13.4.2 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 KVK Tech Inc. Main Business Overview
13.4.5 KVK Tech Inc. Latest Developments
13.5 Gelesis Holdings
13.5.1 Gelesis Holdings Company Information
13.5.2 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Gelesis Holdings Main Business Overview
13.5.5 Gelesis Holdings Latest Developments
13.6 Vivus LLC.
13.6.1 Vivus LLC. Company Information
13.6.2 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Vivus LLC. Main Business Overview
13.6.5 Vivus LLC. Latest Developments
13.7 Currax Pharmaceuticals LLC
13.7.1 Currax Pharmaceuticals LLC Company Information
13.7.2 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Currax Pharmaceuticals LLC Main Business Overview
13.7.5 Currax Pharmaceuticals LLC Latest Developments
13.8 GlaxoSmithKline plc
13.8.1 GlaxoSmithKline plc Company Information
13.8.2 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 GlaxoSmithKline plc Main Business Overview
13.8.5 GlaxoSmithKline plc Latest Developments
13.9 CHEPLAPHARM Arzneimittel GmbH
13.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
13.9.2 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 CHEPLAPHARM Arzneimittel GmbH Main Business Overview
13.9.5 CHEPLAPHARM Arzneimittel GmbH Latest Developments
13.10 Rhythm Pharmaceuticals
13.10.1 Rhythm Pharmaceuticals Company Information
13.10.2 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
13.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Rhythm Pharmaceuticals Main Business Overview
13.10.5 Rhythm Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
Table 1. Peripherally Acting Anti-Obesity Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Peripherally Acting Anti-Obesity Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Prescription Drugs
Table 4. Major Players of Non-prescription Drugs
Table 5. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2018-2023) & (K Units)
Table 6. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
Table 7. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2018-2023) & ($ million)
Table 8. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2018-2023)
Table 9. Global Peripherally Acting Anti-Obesity Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2018-2023) & (K Units)
Table 11. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2018-2023)
Table 12. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2018-2023)
Table 13. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2018-2023)
Table 14. Global Peripherally Acting Anti-Obesity Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Peripherally Acting Anti-Obesity Drug Sales by Company (2018-2023) & (K Units)
Table 16. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Company (2018-2023)
Table 17. Global Peripherally Acting Anti-Obesity Drug Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Company (2018-2023)
Table 19. Global Peripherally Acting Anti-Obesity Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Peripherally Acting Anti-Obesity Drug Producing Area Distribution and Sales Area
Table 21. Players Peripherally Acting Anti-Obesity Drug Products Offered
Table 22. Peripherally Acting Anti-Obesity Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Peripherally Acting Anti-Obesity Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Peripherally Acting Anti-Obesity Drug Sales Market Share Geographic Region (2018-2023)
Table 27. Global Peripherally Acting Anti-Obesity Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Peripherally Acting Anti-Obesity Drug Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Country/Region (2018-2023)
Table 31. Global Peripherally Acting Anti-Obesity Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023) & (K Units)
Table 34. Americas Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2018-2023)
Table 35. Americas Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2018-2023)
Table 37. Americas Peripherally Acting Anti-Obesity Drug Sales by Type (2018-2023) & (K Units)
Table 38. Americas Peripherally Acting Anti-Obesity Drug Sales by Application (2018-2023) & (K Units)
Table 39. APAC Peripherally Acting Anti-Obesity Drug Sales by Region (2018-2023) & (K Units)
Table 40. APAC Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2018-2023)
Table 41. APAC Peripherally Acting Anti-Obesity Drug Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2018-2023)
Table 43. APAC Peripherally Acting Anti-Obesity Drug Sales by Type (2018-2023) & (K Units)
Table 44. APAC Peripherally Acting Anti-Obesity Drug Sales by Application (2018-2023) & (K Units)
Table 45. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023) & (K Units)
Table 46. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2018-2023)
Table 47. Europe Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2018-2023)
Table 49. Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2018-2023) & (K Units)
Table 50. Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Peripherally Acting Anti-Obesity Drug
Table 58. Key Market Challenges & Risks of Peripherally Acting Anti-Obesity Drug
Table 59. Key Industry Trends of Peripherally Acting Anti-Obesity Drug
Table 60. Peripherally Acting Anti-Obesity Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Peripherally Acting Anti-Obesity Drug Distributors List
Table 63. Peripherally Acting Anti-Obesity Drug Customer List
Table 64. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Peripherally Acting Anti-Obesity Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Peripherally Acting Anti-Obesity Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Peripherally Acting Anti-Obesity Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Peripherally Acting Anti-Obesity Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Peripherally Acting Anti-Obesity Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Peripherally Acting Anti-Obesity Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Peripherally Acting Anti-Obesity Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Peripherally Acting Anti-Obesity Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Novo Nordisk A/S Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 80. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Novo Nordisk A/S Main Business
Table 82. Novo Nordisk A/S Latest Developments
Table 83. Pfizer Inc. Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 85. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Pfizer Inc. Main Business
Table 87. Pfizer Inc. Latest Developments
Table 88. Boehringer Ingelheim International GmbH Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 90. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Boehringer Ingelheim International GmbH Main Business
Table 92. Boehringer Ingelheim International GmbH Latest Developments
Table 93. KVK Tech Inc. Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 95. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. KVK Tech Inc. Main Business
Table 97. KVK Tech Inc. Latest Developments
Table 98. Gelesis Holdings Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 100. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Gelesis Holdings Main Business
Table 102. Gelesis Holdings Latest Developments
Table 103. Vivus LLC. Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 105. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Vivus LLC. Main Business
Table 107. Vivus LLC. Latest Developments
Table 108. Currax Pharmaceuticals LLC Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 110. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Currax Pharmaceuticals LLC Main Business
Table 112. Currax Pharmaceuticals LLC Latest Developments
Table 113. GlaxoSmithKline plc Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 115. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. GlaxoSmithKline plc Main Business
Table 117. GlaxoSmithKline plc Latest Developments
Table 118. CHEPLAPHARM Arzneimittel GmbH Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 120. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. CHEPLAPHARM Arzneimittel GmbH Main Business
Table 122. CHEPLAPHARM Arzneimittel GmbH Latest Developments
Table 123. Rhythm Pharmaceuticals Basic Information, Peripherally Acting Anti-Obesity Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolios and Specifications
Table 125. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Rhythm Pharmaceuticals Main Business
Table 127. Rhythm Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Peripherally Acting Anti-Obesity Drug
Figure 2. Peripherally Acting Anti-Obesity Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peripherally Acting Anti-Obesity Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Peripherally Acting Anti-Obesity Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Peripherally Acting Anti-Obesity Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Prescription Drugs
Figure 10. Product Picture of Non-prescription Drugs
Figure 11. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type in 2022
Figure 12. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2018-2023)
Figure 13. Peripherally Acting Anti-Obesity Drug Consumed in Hospital Pharmacies
Figure 14. Global Peripherally Acting Anti-Obesity Drug Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 15. Peripherally Acting Anti-Obesity Drug Consumed in Retail Pharmacies
Figure 16. Global Peripherally Acting Anti-Obesity Drug Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 17. Peripherally Acting Anti-Obesity Drug Consumed in Online Pharmacies
Figure 18. Global Peripherally Acting Anti-Obesity Drug Market: Online Pharmacies (2018-2023) & (K Units)
Figure 19. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2022)
Figure 20. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application in 2022
Figure 21. Peripherally Acting Anti-Obesity Drug Sales Market by Company in 2022 (K Units)
Figure 22. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Company in 2022
Figure 23. Peripherally Acting Anti-Obesity Drug Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Company in 2022
Figure 25. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Peripherally Acting Anti-Obesity Drug Sales 2018-2023 (K Units)
Figure 28. Americas Peripherally Acting Anti-Obesity Drug Revenue 2018-2023 ($ Millions)
Figure 29. APAC Peripherally Acting Anti-Obesity Drug Sales 2018-2023 (K Units)
Figure 30. APAC Peripherally Acting Anti-Obesity Drug Revenue 2018-2023 ($ Millions)
Figure 31. Europe Peripherally Acting Anti-Obesity Drug Sales 2018-2023 (K Units)
Figure 32. Europe Peripherally Acting Anti-Obesity Drug Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue 2018-2023 ($ Millions)
Figure 35. Americas Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2022
Figure 36. Americas Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country in 2022
Figure 37. Americas Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
Figure 38. Americas Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2018-2023)
Figure 39. United States Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Peripherally Acting Anti-Obesity Drug Sales Market Share by Region in 2022
Figure 44. APAC Peripherally Acting Anti-Obesity Drug Revenue Market Share by Regions in 2022
Figure 45. APAC Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
Figure 46. APAC Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2018-2023)
Figure 47. China Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2022
Figure 55. Europe Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country in 2022
Figure 56. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
Figure 57. Europe Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2018-2023)
Figure 58. Germany Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Peripherally Acting Anti-Obesity Drug Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2018-2023)
Figure 67. Egypt Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Peripherally Acting Anti-Obesity Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Peripherally Acting Anti-Obesity Drug in 2022
Figure 73. Manufacturing Process Analysis of Peripherally Acting Anti-Obesity Drug
Figure 74. Industry Chain Structure of Peripherally Acting Anti-Obesity Drug
Figure 75. Channels of Distribution
Figure 76. Global Peripherally Acting Anti-Obesity Drug Sales Market Forecast by Region (2024-2029)
Figure 77. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Peripherally Acting Anti-Obesity Drug Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share Forecast by Application (2024-2029)